NASDAQ : AURA
Aura Biosciences, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 6.295 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 652.82M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 636.75M |
| Enterprise Value | 329.50M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 103.70M |
| Shares Outstanding | 103.70M |
| Shares Change (YoY) | +42.27% |
| Shares Change (QoQ) | +40.65% |
| Owned by Insiders (%) | 1.20% |
| Owned by Institutions (%) | 68.13% |
| Float | 74.64M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.02 |
| P/TBV Ratio | 2.02 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 16.82 |
| Quick Ratio | 16.65 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -53.49% |
| Return on Assets (ROA) | -31.24% |
| Return on Invested Capital (ROIC) | -32.90% |
| Return on Capital Employed (ROCE) | -42.02% |
| Weighted Average Cost of Capital (WACC) | 6.52% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.16M |
| Employee Count | 113 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 81,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.44 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 6.68 |
| 200-Day Moving Average | 6.72 |
| Relative Strength Index (RSI) | 42.64 |
| Average Volume (20 Days) | 847,870 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 10.89M |
| Short Previous Month | 10.37M |
| Short % of Shares Out | 10.50% |
| Short % of Float | 14.58% |
| Short Ratio (days to cover) | 10.19 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -138.08M |
| Pretax Income | -130.93M |
| Net Income | -131.01M |
| EBITDA | -136.99M |
| EBIT | -138.08M |
| Earnings Per Share (EPS) | -$1.77 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 323.84M |
| Total Debt | 16.59M |
| Net Cash | 307.25M |
| Net Cash Per Share | $2.96 |
| Equity (Book Value) | 315.27M |
| Book Value Per Share | 3.05 |
| Working Capital | 309.47M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -103.01M |
| Capital Expenditures | -344,000 |
| Depreciation & Amortization | 1.09M |
| Net Borrowing | n/a |
| Free Cash Flow | -103.35M |
| FCF Per Share | -$1.00 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -42.27% |
| Shareholder Yield | n/a |
| Earnings Yield | -28.87% |
| FCF Yield | -16.23% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $16.60 |
| Price Target Difference | 170.36% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |